UroGen Pharma Ltd. - Ordinary Shares (URGN) Covered Calls

You can sell covered calls on UroGen Pharma Ltd. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for URGN (prices last updated Fri 4:16 PM ET):

UroGen Pharma Ltd. - Ordinary Shares (URGN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
10.64 -0.07 10.50 11.41 1.4M - 0.5
Covered Calls For UroGen Pharma Ltd. - Ordinary Shares (URGN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Jan 17 10 0.00 11.41 -12.4% -156.1%
Feb 21 10 0.55 10.86 -7.9% -45.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.